AstraZeneca Takes Impairment Charge After Olaparib, TC-5214 Setbacks
This article was originally published in The Pink Sheet Daily
Executive Summary
Olaparib and TC-5214 development setbacks at AstraZeneca lead to $380 million charge in the fourth quarter, with core EPS likely at the bottom of the expected range.
You may also be interested in...
Olaparib Review Renews Debate On Maintenance Therapy Endpoints
Oncologic Drugs Advisory Committee members divided on whether progression-free survival endpoint in AstaZeneca’s Phase III SOLO-2 trial could be used to support approval for maintenance therapy in relapsed ovarian cancer.
FDA Questions Accelerated Approval For AstraZeneca’s Olaparib In Ovarian Cancer
Oncologic Drugs Advisory Committee will consider whether the first-in-class PARP inhibitor should come to market on the basis of Phase II data in a subgroup of patients or await results from an ongoing confirmatory study. Agency cites “uncertainties” about validity and magnitude of effect seen in the Phase II trial.
AstraZeneca Back In The PARP Mix With Olaparib In Ovarian Cancer
Olaparib is off the shelf and into a Phase III trial against ovarian cancer in platinum-sensitive BRCA-positive patients, adding to the list of late-stage PARP inhibitors vying for first-in-class status.